Analyst Ratings for Biogen (BIIB)
BIIB Rating Summary
BIIB Price Target Summary
- Highest: $398.00 (Goldman Sachs)
- Lowest: $214.00 (UBS)
- Average: $294.54
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$294.54 (+53%)
* Over Last 12-Mos
Rating Score: 6.9 / 10
Percentile Rank: 75%
Avg. $ Target:
$294.54 (+53%)
* Over Last 12-Mos
Rating Score: 6.9 / 10
Percentile Rank: 75%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/14/2024 | Wells Fargo | Mohit Bansal | Downgrade | Equal Weight (Overweight) |
240.00 (315.00) |
226.65 (192.53) |
-15.05% | Details |
| 1/24/2024 | UBS » Updated 4/17/2024 |
Colin Bristow | Downgrade | Neutral (Buy) |
214.00 (250.00) |
251.68 (192.53) |
-23.5% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
